VivoSeq
Immunology

Food Allergy

17

Pipeline Programs↗

10

Active Trials↗

7

Companies Involved↗

Food Allergy is an emerging landscape with 17 programs across 7 companies. The most active players are Pfizer, RAPT Therapeutics, Inc., Novartis. 4 therapies are approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

47/100

Pipeline Velocity

15/100

Mech. Concentration

33/100

Completion Rate

90/100

Attrition Rate

4/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

1 program

Phase 1R

RAPT Therapeutics, Inc.

1 program

Phase 2Novartis logo

Novartis

1 program

Phase 3Roche logo

Roche

1 program

Phase 3Regeneron logo

Regeneron

2 programs

Phase 3AstraZeneca logo

AstraZeneca

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

71%

Small molecule

12 of 17 classified programs — the dominant modality here.

29%ALL OTHERSMonoclonal antibody529%

Small molecule leads; the ring shows all 17 classified programs, each share of the total. Modality classified for 100% of 20 pipeline programs.

Analysis

Trial Status

23

clinical trials

Completed9 · 39%
Recruiting6 · 26%
Active, not recruiting3 · 13%
Unknown status2 · 9%
Terminated1 · 4%
Not yet recruiting1 · 4%
Other1 · 4%

Clinical Trials

Trial Activity

23 trials

Effect of Omalizumab in the Skin of Food Allergy Patients
Recruiting·NNational Jewish Health·Phase 4·NCT06618963·40 enrolled
Omalizumab for the Treatment of Food Allergy in Patients With Elevated Total IgE Levels
Recruiting·JJohns Hopkins University·Phase 2·NCT06934200·32 enrolled
Prescreening Protocol to Enroll in Food Allergy Clinical Studies at a Single Site
Recruiting·SStanford University·N/A·NCT03539692·1,000 enrolled
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy
Recruiting·RRAPT Therapeutics, Inc.·Phase 2·NCT07220811·100 enrolled
Natural History and Genetics of Food Allergy and Related Conditions
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT02504853·1,800 enrolled
Early Introduction and Sustained Ingestion (EISI) Using Two Educational Opportunities - A Pilot Study
Recruiting·SStanford University·Preclinical·NCT07321522·92 enrolled
Can Vitamin D Supplementation in the First Year of Life Prevent Food Allergy in Infants? The VITALITY Trial: Parts 1&2
Active, not recruiting·MMurdoch Childrens Research Institute·Phase 4·NCT02112734·2,739 enrolled
The PEBBLES Study - Testing a Strategy for Preventing Eczema and Food Allergy in High Risk Infants
Active, not recruiting·UUniversity of Melbourne·Phase 3·NCT03667651·760 enrolled
A Phase 1 Dose-Escalation Study in Adults With Severe IgE-Mediated Food Allergy, to Assess the Safety, Tolerability, and Pharmacodynamic Effects of Short-Term Linvoseltamab Treatment, a BCMAxCD3 Bispecific Antibody to Induce T-Cell Killing of IgE Producing Plasma Cells, on Top of Chronic Dupilumab Treatment, to Prevent the Formation of New IgE Producing Plasma Cells
Active, not recruiting·Regeneron logoRegeneron·Phase 1·NCT06369467·6 enrolled
Omalizumab for Plant-Food Allergy Due to Sensitization to LTP or Profilin
Not yet recruiting·FFundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud·N/A·NCT07073404·37 enrolled
Basophil Activation Test (BAT) Sensitivity in Child Food Allergy
Completed·UUniversity Hospital, Rouen·Phase 4·NCT01966640·140 enrolled
Single Center Food Allergy Oral Immunotherapy Study
Completed·SStanford University·Phase 1·NCT01490177·50 enrolled
Effects of Montelukast in Asthmatic Children With and Without Food Allergy
Completed·HHacettepe University·Phase 4·NCT01618929·113 enrolled
Influence of Persistent Food Allergy on Nutritional Status of Children With Food Allergy
Completed·UUniversity Medical Centre Ljubljana·N/A·NCT05937061·130 enrolled
Omalizumab in Severe Asthmatics With Food Allergy
Completed·—·N/A·NCT06316414·65 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)